ResearcherAnhui Medical UniversityActive in the last 2 years
Mengjie Lv
Matched on ORCID iD 0009-0002-2187-1967; OpenAlex author ID A5138802953. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2025: 1 paper · 2026: 2 papers
Papers 3
- Tetrastigma hemsleyanum ELN-derived miR-396b suppresses pancreatic cancer cell proliferation by targeting IL33. Co-author DOI 10.1016/j.bbrc.2026.154163↗
- Targeting HAS2 to enhance anti-tumor immunity in pancreatic cancer via PD-L1 regulation. Co-author DOI 10.1038/s42003-026-10009-1↗
- Cancer-Associated Fibroblast-Centric Risk Model Predicts Immunotherapy Resistance in Pancreatic Cancer and Reveals PLOD2 as a Key Stromal Therapeutic Target. Co-author DOI 10.31083/fbl46316↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Daoxiang Zhang · 3 shared papers, 2025–2026 · strength 0.85
- Paper Tetrastigma hemsleyanum ELN-derived miR-396b suppresses pancreatic cancer cell proliferation by targeting IL33. DOI 10.1016/j.bbrc.2026.154163↗
- Paper Cancer-Associated Fibroblast-Centric Risk Model Predicts Immunotherapy Resistance in Pancreatic Cancer and Reveals PLOD… DOI 10.31083/fbl46316↗
- Paper Targeting HAS2 to enhance anti-tumor immunity in pancreatic cancer via PD-L1 regulation. DOI 10.1038/s42003-026-10009-1↗
- Pengwei Cao · 2 shared papers, 2025–2026 · strength 0.46
- Fubao Liu · 1 shared paper, 2025 · strength 0.24
- Chuifang Kong · 1 shared paper, 2026 · strength 0.23
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.